The Globe and Mail reports in its Friday edition that National Bank Financial analyst Zachary Evershed continues to rank Dexterra Group "outperform." The Globe's David Leeder writes in the Eye On Equities column that Mr. Evershed advanced his share target by a loonie to $16.50. Analysts on average target the shares at $15.25. Mr. Evershed sees "nation building and defence tailwinds gathering" for Dexterra, touting an "attractive entry with or without federal spending." Mr. Evershed says in a note: "While management acknowledged growing tailwinds, our forecasts do not yet include any assumed wins in the nation building and defence arenas, leaving substantial upside potential as the industry expects near-term opportunities to come to fruition in late 2026, with a spectrum of projects thereafter in 2027 and 2028. ... With approximately 22k beds under management and combined utilization on 12k owned beds (including Right Choice) in the high-80s, Dexterra has available capacity to pursue mega projects. Availability can be further stretched through incremental rationalization in the Montney/Duvernay region, as beds are released when projects conclude, and even through purchase and refurbishment of equipment in the market."